Member Info for sweepie3

If I get them at the same price as the Chairman I might buy a few and sit it out while they remain as a private company, just purely as a gamble

So it will probably fail then and then I see the Chairman has purchased shares at 1p which is a bit rich when the placing is 3 x the price, think I will watch for now until it delists, thanks for the warning

With the bid halve the placing price now, what does that tell us about the future I wonder

Major Milestone for Zenova Group PLC 🚨

We’re proud to announce that Zenova SEE Sh.p.k, our joint venture in South-Eastern Europe, has officially commenced full-scale production and initial sales of the Zenova CS ceiling-mounted fire suppression unit at our newly commissioned manufacturing facility in Albania.

This is a significant step in our mission to localise manufacturing across the EMEA region, delivering advanced fire safety technologies closer to the point of need. The facility will act as a strategic hub, supplying Zenova CS units throughout the Balkans and wider European markets.

What makes this special?

Production brought online at impressive speed

First deliveries expected in Q3 2025

Fully aligned with Zenova’s stringent QA protocols

Lower logistics costs and faster deployment

Powered by our non-toxic, proprietary suppression agent

Remember they have to take production costs out as well as its probably a 50:50 share but if they could do the same deal with other local partners then it will become a licence to print money but at this stage its a big IF

Get into America then it would be game on

Completely missed by the market todays RNS, great name to have on the register and with Zenova getting involved with public services both here and abroad you would hope that we have seen the bottoms and none of the future success priced in so upwards from here. Peel Hunt obviously can see a growth story here or they wouldn't have bought in

Zenova and AED Form Joint Venture to Establish Manufacturing Facility in Albania Amid Growing Regional Demand

JV Expected to Generate Over E2m Over the First Full Year of Operations From May 2025

Zenova Group PLC (AIM: ZED), a leading innovator in fire suppression and temperature management solutions, is pleased to announce the formation of a joint venture with its local sub-distributor, AED Sh.p.K, to establish a new manufacturing facility in Albania. This strategic initiative is designed to support accelerating demand for Zenova's product suite in Albania and surrounding markets, following strong initial sales delivered by AED.

Zenova expects that this manufacturing facility will be fully operational by the middle of May servicing demand AED have developed in the region, and thus the joint venture is projected to generate revenues exceeding €2 million in the first 12 months. This early demand is expected to be supported by a strong and expanding pipeline of opportunities across key sectors including construction, infrastructure, and government.

AED has made a significant financial commitment to the project and is actively driving business development efforts to support long-term growth.

The facility, located just outside Tirana, has been secured and upgraded by AED to include a purpose-built, two-storey laboratory and office space. Production equipment tailored for Zenova's exclusive range of fire-resistant and temperature management products has arrived from the UK and is currently being offloaded. Installation and commissioning of the equipment will be overseen by a Zenova-appointed consultant, who will also lead the training of local staff to ensure operational excellence from the outset.

The facility is expected to be fully operational by mid-May and will enable Zenova to efficiently supply the Albanian and surrounding markets, eliminating the delays and costs associated with cross-border trade.

Thomas Melchior, CEO of Zenova Group PLC, commented:"This joint venture marks a major step forward in Zenova's European expansion strategy. AED has already demonstrated the marke'st appetite for our solutions, and with this new facility, we can respond to that demand faster and more efficiently. We greatly value AED's investment and commitment to date, and their proactive business development across high-potential sectors. Together, we are well positioned to unlock the full commercial potential of the region."

Be surprised or an oversight as they have just raised £250,000

Doubt we will be able to keep up with the buying today despite the general sentiment on the market due to Trump tarifs

5. What are your immediate goals during this Silicon Valley tenure?

We have three key objectives for our time in Silicon Valley:

Forge strategic partnerships with tech and healthcare leaders.

Attract top US-based talent to strengthen our expertise.

Engage with investors who share our vision for transforming pharmaceutical marketing through AI-driven insights.

Being in the Valley allows us to stay at the cutting edge of AI and healthcare innovation, ensuring that our solutions continue to lead in the industry.

6. How do you envision the future of Talking Medicines in the US?

Our vision is to be an integral part of the US healthcare ecosystem, providing pharma with the most advanced AI-powered intelligence tools to better understand and engage with HCPs and patients. By bridging the gap between real-world experiences and pharma decision-making, we aim to improve patient outcomes and contribute to a more patient-centered healthcare system.

Let’s Connect

This week has reinforced the scale of the opportunity ahead and our commitment to driving innovation at the intersection of AI and healthcare. We’re actively meeting with partners, investors, and industry leaders—if you’d like to connect, please reach out to:

📩 jo@talkingmedicines.com

Jo Halliday (CEO), Scott Crae (Partnerships), and Elizabeth Fairley (CDO/COO) are available for meetings—let’s discuss how we can collaborate to shape the future of AI-driven healthcare intelligence.

Talking Medicines has taken a high-profile residency in Silicon Valley as part of the Scottish Government/SDI Market Booster Program, marking a significant step in accelerating our US growth. This initiative places us at the heart of the world’s leading tech and innovation hub, allowing us to deepen our engagement with industry pioneers and expand our reach within the US healthcare ecosystem.

After our first week in the Valley, here are some of the most common questions I’ve been asked—and my reflections on what this expansion means for Talking Medicines.

1. What motivated Talking Medicines to expand into the US market?

The US is the global leader in the pharmaceutical industry, making it a natural next step for our growth. We’ve already established a legal entity and headquarters in New York, bringing us closer to our customer base. Now, having successfully built our East Coast foundations, we’re looking westward—to Silicon Valley—to explore further opportunities, connect with tech leaders, and engage with new customers in the region.

2. How does Silicon Valley’s ecosystem align with Talking Medicines’ objectives?

Silicon Valley is a powerhouse for AI, data science, and innovation—the very core of what we do. Our US Market Booster residency is a strategic move to accelerate collaboration with leading tech innovators, enhance our patient-centric AI solutions, and explore new frontiers in health and wellness intelligence. The Valley offers a unique environment to scale our impact and connect with global thought leaders who are shaping the future of AI-driven healthcare.

3. What challenges do you anticipate in the US healthcare landscape?

The complexity of the US healthcare system presents both challenges and opportunities. At Talking Medicines, we bring deep expertise in navigating regulatory frameworks, understanding diverse HCP (healthcare professional) and patient demographics, and implementing structured processes to deliver actionable intelligence. These challenges also fuel innovation, allowing us to refine and adapt our solutions to meet the unique needs of the US market.

4. How does Talking Medicines differentiate itself from competitors?

What sets us apart is our ability to translate HCP and patient experiences into real-world intelligence for pharmaceutical marketers and agency strategists. By harnessing Advanced Data Science and AI, we provide unparalleled insights into patient and HCP sentiment—ultimately helping pharma companies create more effective, targeted marketing strategies and drive improved patient outcomes.

Zenova expects to be a particularly productive period across mainland Europe as tougher product specifications and tightening environmental regulations increasingly prevail.

If this is right then 2025 could be Zenovas year but there is one hell of an overhang and therefore these halve decent updates are going to have to continue as well as settle nerves of any placings at these highly dilutive levels

The company realizes that it made a mistake in disclosing the amount but did so to highlight the deepening relationship with a name distributor, to counter BB chatter that they were not doing restocking orders. News coming this afternoon or Monday

Https://www.youtube.com/watch?v=D9xbbdQYoy0

Zenova Group PLCZenova Group PLC

484 followers484 followers

18h • 18 hours ago

Follow

I'm excited to see Zenova's global expansion into Chile, where our full range of products was showcased to industry leaders, potential customers, and experts.

hashtag#Firesafety hashtag#Chile hashtag#wildfire hashtag#ChileanMarket hashtag#BusinessExpansion hashtag#fireextinguisher

hxxps://lnkd.in/dBnXvQXW

RECAP ECOZENOVA CHILE

youtube.co

Good news but a letter of intent usually has so many get out clauses that it rarely gives a huge swing, should be up by a bit though

The company claims that the CEO was removed because of the missing orders and in any case CFO are rarely involved in orders and if you had read it properly you would have read that I did say nearly when describing the BoDs in charge at the time of these suspect orders. As you wish misfortune on anybody who goes against your troll thinking, you have been placed on the filter list. No doubt you will come back with a few names but remember I won't be able to read them

The previous CEO was removed because of the previous orders disappearing, new team largely in charge and want to move on from the past. If they make it then there is a fair amount of upside here of course there is 100% downside but imho having received the FX500 their product is pretty good, their videos back this up so willing to give them a chance

Big BLUE day ahead!!!!

They have told us a material order will be released very soon, there have already released several smaller orders and you would have thought that 20 distributors would be bringing in some business plus a tax rebate, it all adds up

Zenova Group PLC Enters New Market with Major Demonstration in Chile

Zenova Group PLC (AIM: ZED), an innovation leader in fire suppression and temperature management solutions, is pleased to announce that its Latin American distribution partner, EZ International, recently hosted a major demonstration event in Chile for local fire safety professionals, industry buyers, and large potential customers.

The event showcased demonstrations of Zenova's complete range of innovative solutions, including the Zenova IP and FP thermal and fire protection coatings, along with the full suite of Zenova FX extinguishers. The highlight of the day was a striking ground fire demonstration, with Zenova's WB fluid deployed by drone for rapid and effective fire suppression.

Gabriel Coll, Vice President of Eco-Zenova International,"We intentionally chose this location in Chile for our latest Zenova product demonstration, as regional experts are increasingly looking for innovative solutions to address the growing frequency of fire events driven by climate change. The overwhelmingly positive response to the performance and effectiveness of Zenova's solutions is expected to significantly boost demand for our products across Latin America."

Thomas Melchior, CEO of Zenova Group PLC, commented, "EZI is a strategic partner propelling our international growth. Product demonstrations to key clients are the most effective way to secure customer acceptance, and EZI's efforts in showcasing our innovations are accelerating our global expansion strategy. The positive feedback from customers gives me strong confidence that we will soon announce initial orders from this region."